Economic value of dengue vaccine in Thailand.

TitleEconomic value of dengue vaccine in Thailand.
Publication TypeJournal Article
Year of Publication2011
AuthorsLee BY, Connor DL, Kitchen SB, Bacon KM, Shah M, Brown ST, Bailey RR, Laosiritaworn Y, Burke DS, Cummings DAT
JournalAm J Trop Med Hyg
Volume84
Issue5
Pagination764-72
Date Published2011 May
ISSN1476-1645
KeywordsCost-Benefit Analysis, Dengue, Dengue Vaccines, Humans, Thailand
Abstract

With several candidate dengue vaccines under development, this is an important time to help stakeholders (e.g., policy makers, scientists, clinicians, and manufacturers) better understand the potential economic value (cost-effectiveness) of a dengue vaccine, especially while vaccine characteristics and strategies might be readily altered. We developed a decision analytic Markov simulation model to evaluate the potential health and economic value of administering a dengue vaccine to an individual (≤ 1 year of age) in Thailand from the societal perspective. Sensitivity analyses evaluated the effects of ranging various vaccine (e.g., cost, efficacy, side effect), epidemiological (dengue risk), and disease (treatment-seeking behavior) characteristics. A ≥ 50% efficacious vaccine was highly cost-effective [< 1× per capita gross domestic product (GDP) ($4,289)] up to a total vaccination cost of $60 and cost-effective [< 3× per capita GDP ($12,868)] up to a total vaccination cost of $200. When the total vaccine series was $1.50, many scenarios were cost saving.

DOI10.4269/ajtmh.2011.10-0624
Alternate JournalAm. J. Trop. Med. Hyg.
PubMed ID21540387
PubMed Central IDPMC3083745
Grant List5U54GM088491-02 / GM / NIGMS NIH HHS / United States
U54 GM088491 / GM / NIGMS NIH HHS / United States
Publication Categories: